IRLA — IRulya Therapeutics Share News
0.000.00%
Last trade - 00:00- $355.93m
- $383.76m
Brief: Quince Therapeutics Files For Mixed Shelf Offering Of Up To $200 Million - SEC Filing
Brief: Quince Therapeutics Regains Compliance With Nasdaq Listing Rule
Quince Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
Quince Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Quince Therapeutics Announces The Lancet Neurology Publication Of Phase 3 ATTeST Clinical Trial Data Evaluating Erydex
Brief: Quince Therapeutics Announces First Patient Dosed In Phase 3 Clinical Trial
Brief: Quince Therapeutics Receives U.S. FDA Fast Track Designation For EryDex System
Brief: Quince Therapeutics Compensation Committee Determines Executive Officers Would Receive No Salary Increase For 2024
Brief: Quince Therapeutics Board Approves Termination Of License Agreement By And Between Co, Purdue Research Foundation
Brief: Genextra S.p.A. Reports 5.89% Passive Stake In Quince Therapeutics As Of Oct 20
Brief: Quince Therapeutics Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Brief: U.S. FDA Lifts Partial Hold On Application For Lead Drug
Quince rises as FDA lifts partial hold on late-stage study for lead drug
U.S. STOCKS ON THE MOVE-General Motors, Estee Lauder, IMAX
U.S. STOCKS ON THE MOVE-PaxMedica, Heron, Belite Bio
U.S. STOCKS ON THE MOVE-Apple, Quince, Syndax Pharma
Quince up on deal to buy biotech EryDel SpA, its lead drug candidate
Brief: Quince Therapeutics Board Rejects Proposal From Echo Lake Capital